Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Sci. STKE, 14 June 2005
Vol. 2005, Issue 288, p. pe27
[DOI: 10.1126/stke.2882005pe27]

PERSPECTIVES

Crossroads of Estrogen Receptor and NF-{kappa}B Signaling

Debajit K. Biswas*, Sindhu Singh, Qian Shi, Arthur B. Pardee, and J. Dirk Iglehart

Department of Cancer Biology, Dana-Farber Cancer Institute, and Department of Surgery, Brigham and Women’s Hospital, Boston, MA 02115, USA.

Summary: Cellular homeostasis in higher organisms is maintained by balancing cell growth, differentiation, and death. Two important systems that transmit extracellular signals into the machinery of the cell nucleus are the signaling pathways that activate nuclear factor {kappa}B (NF-{kappa}B) and estrogen receptor (ER). These two transcription factors induce expression of genes that control cell fates, including proliferation and cell death (apoptosis). However, ER has anti-inflammatory effects, whereas activated NF-{kappa}B initiates and maintains cellular inflammatory responses. Recent investigations elucidated a nonclassical and nongenomic effect of ER: inhibition of NF-{kappa}B activation and the inflammatory response. In breast cancer, antiestrogen therapy might cause reactivation of NF-{kappa}B, potentially rerouting a proliferative signal to breast cancer cells and contributing to hormone resistance. Thus, ER ligands that selectively block NF-{kappa}B activation could provide specific potential therapy for hormone-resistant ER-positive breast cancers.

*Corresponding author. E-mail: Debajit_Biswas{at}dfci.harvard.edu

Citation: D. K. Biswas, S. Singh, Q. Shi, A. B. Pardee, J. D. Iglehart, Crossroads of Estrogen Receptor and NF-{kappa}B Signaling. Sci. STKE 2005, pe27 (2005).

Read the Full Text

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation.
M. Takahashi, F. Otsuka, T. Miyoshi, H. Otani, J. Goto, M. Yamashita, T. Ogura, H. Makino, and H. Doihara (2008)
J. Endocrinol. 199, 445-455
   Abstract »    Full Text »    PDF »
ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor {alpha} expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells.
M. Honorat, A. Mesnier, J. Vendrell, J. Guitton, I. Bieche, R. Lidereau, G. D Kruh, C. Dumontet, P. Cohen, and L. Payen (2008)
Endocr. Relat. Cancer 15, 125-138
   Abstract »    Full Text »    PDF »
Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells.
J.-M. Renoir, C. Bouclier, A. Seguin, V. Marsaud, and B. Sola (2008)
J. Mol. Endocrinol. 40, 101-112
   Abstract »    Full Text »    PDF »
Cyclic Regulation of T-Bet and GATA-3 in Human Endometrium.
D. Inman, K. Kawana, D. Schust, R. Lininger, and S. Young (2008)
Reproductive Sciences 15, 83-90
   Abstract »    PDF »
Nuclear factor-{kappa}B activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer.
S. Singh, Q. Shi, S. T. Bailey, M. J. Palczewski, A. B. Pardee, J. D. Iglehart, and D. K. Biswas (2007)
Mol. Cancer Ther. 6, 1973-1982
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882